Q3 EPS Forecast for Sensus Healthcare Increased by Analyst

Sensus Healthcare, Inc. (NASDAQ:SRTS) – HC Wainwright upped their Q3 2025 earnings estimates for Sensus Healthcare in a research report issued to clients and investors on Monday, November 18th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of $0.08 per share for the quarter, up from their prior estimate of $0.03. HC Wainwright currently has a “Buy” rating and a $11.00 target price on the stock. The consensus estimate for Sensus Healthcare’s current full-year earnings is $0.38 per share. HC Wainwright also issued estimates for Sensus Healthcare’s Q4 2025 earnings at $0.20 EPS.

Separately, Maxim Group raised their price target on Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Friday, November 15th.

Sensus Healthcare Price Performance

Shares of NASDAQ SRTS opened at $8.37 on Wednesday. The business has a fifty day moving average price of $6.42 and a two-hundred day moving average price of $6.00. The stock has a market capitalization of $137.10 million, a PE ratio of 14.75 and a beta of 1.04. Sensus Healthcare has a fifty-two week low of $2.02 and a fifty-two week high of $8.69.

Institutional Investors Weigh In On Sensus Healthcare

A number of large investors have recently modified their holdings of SRTS. Truvestments Capital LLC acquired a new stake in Sensus Healthcare in the third quarter valued at about $32,000. Chapin Davis Inc. acquired a new position in Sensus Healthcare during the 2nd quarter worth approximately $53,000. XTX Topco Ltd bought a new position in Sensus Healthcare in the 2nd quarter valued at approximately $95,000. Cubist Systematic Strategies LLC bought a new stake in shares of Sensus Healthcare during the second quarter worth $156,000. Finally, Acadian Asset Management LLC lifted its stake in shares of Sensus Healthcare by 578.6% in the 2nd quarter. Acadian Asset Management LLC now owns 45,124 shares of the company’s stock valued at $239,000 after acquiring an additional 38,474 shares during the last quarter. Institutional investors and hedge funds own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.